Log in |
Takashi Yoshida MD, Hidefumi Kinoshita MD, PhD, Katsuya Fukui MD, Tomoaki Matsuzaki MD, Kenji Yoshida MD, PhD, Takao Mishima MD, Masaaki Yanishi MD, Yoshihiro Komai MD, PhD, Motohiko Sugi MD, Takaaki Inoue MD, Takashi Murota MD, Tadashi Matsuda MD, PhD
View full article HTML | View full article PDF | Download Citation
Renin-angiotensin system blockade has been effective for the treatment of patients with several types of malignancy. This study evaluated the prognostic impact of renin-angiotensin system inhibitors, including angiotensin-2 converting enzyme inhibitors and angiotensin 2 receptor blockers, in patients with bladder cancer undergoing radical cystectomy.
This retrospective study included 269 patients who had undergone radical cystectomy. The oncologic outcomes of patients treated or not treated with renin-angiotensin system inhibitors after surgery were evaluated. Overall survival and cancer-specific survival were assessed by the Kaplan–Meier method and by Cox regression analysis.
The median follow-up duration after radical cystectomy in survivors was 44.5 months. The 5-year, cancer-specific survival rates in patients who did and did not receive renin-angiotensin system inhibitors were 79.0 and 66.4 %, respectively (P = 0.011). Similarly, the 5-year overall survival rates were 76.1 and 61.4 %, respectively (P = 0.0097). Multivariable analyses showed that use of renin-angiotensin system inhibitors was an independent prognostic factor for cancer-specific survival (hazard ratio 0.47, P = 0.036) and for overall survival (hazard ratio 0.36, P = 0.022).
Renin-angiotensin system inhibitors significantly reduced the risks of cancer-specific and overall mortality after radical cystectomy in patients with bladder cancer. Renin-angiotensin system inhibitors may improve oncologic outcomes in high-risk patients with bladder cancer.
Go to Issue Contents
Add this article to your Personal Archive
Follow the journal on Twitter and help to expand the reach of the journal to help surgical oncologists and their patients.
Annals of Surgical Oncology is copyrighted by the Society of Surgical Oncology
© Springer Healthcare Ltd. A part of Springer Science+Business Media